PMDI · Psychemedics Corp
Market Cap
$15.21M
Shares
6.11M
Volume · Oct 8
99
Avg daily vol (3 sessions)
99
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.49
Open$2.49
Day$2.49–2.49
52W close$1.38–2.50
Avg vol 30d8K
Short int3K · 0.1% float · 999+d
Short vol12%
DataJan 2020–Oct 2026
Filing10-K · Mar 24
Up next
filed Mar 24, 2025
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$19.68M
Trailing 12 months
Net income (TTM)
−$1.86M
Trailing 12 months
Revenue growth YoY
-11.5%
Year over year
Operating margin
-9.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
5.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.13M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.1%
Year over year · more shares
Price change (1Y)
+18.0%
Trailing year
Short interest
0.1%
Latest settlement · 999+ days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
+32%
above
RSI (14)
64
neutral
MACD trend
Positive
52-week position
99%
near high
Momentum
relative strength
1-month return
0%
trailing
6-month return
+8%
trailing
YTD return
+56%
this year
Relative strength
−1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.06% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Squeeze score
44
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
Gross margin
18%
contracting
EPS growth
−58%
Y/Y
Free cash flow
$878.0K
Balance sheet
$4.0M
net debt
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
4.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
+32%
Bullish
RSI (14)
64
Neutral
MACD trend
Positive
Bullish
52-week position
99%
Bullish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
0% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.06% of float · ▬ 0.0% MoM · 1000.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $2 · 99%
Range high $3
vs 200-day avg +20%
vs 50-day avg +32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMDI
this stock
Psychemedics Corp
|
$15.21M | +55.6% | +1.8% | — | 0.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$251.20B | +18.6% | +14.5% | 36.6 | 1.5% |
|
DHR
Danaher Corp /De/
|
$157.77B | -2.0% | +8.5% | 39.8 | 1.3% |
|
NTRA
Natera, Inc.
|
$57.57B | +77.2% | -2.8% | — | 4.4% |
|
A
Agilent Technologies, Inc.
|
$48.56B | +27.1% | +6.4% | 33.9 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMDI | +13.2% | -0.4% | +8.3% | +0.0% | +55.6% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | +11.9% | -2.5% | -0.7% | -1.5% | +42.1% |